Jan 12, 2026
Jan 8, 2026
FineHeart secures €83 million to support its growth and establish itself as a future European leader in Active Implantable Medical Devices (AIMDs)
Jan 8, 2026
Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study
Jan 6, 2026
Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation
Oct 28, 2025
Cardiosense Presents New Clinical Analysis of SEISMIC-HF I Data on AI-Enabled Volume Assessment in Heart Failure at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 Scientific Symposium
Oct 22, 2025